Group 1 - The company Weigao Group (01066) announced a share buyback on February 13, 2026, spending HKD 830,600 to repurchase 160,000 shares at a price range of HKD 5.15 to HKD 5.23 per share [1]

Key Points - The company plans to utilize up to 2 billion yuan of idle funds for purchasing high-security, liquid financial products in 2026 to enhance capital efficiency [2] - The company intends to conduct foreign exchange derivative trading with a limit of up to 500 million USD in 2026, primarily for hedging against exchange rate risks [2] - The company and its subsidiaries plan to engage in commodity futures hedging through a related party, with a maximum trading margin of 500,000 yuan for 2026 [2] Business Status - The company is focusing on product innovation and market expansion in the smart medical and pet economy sectors, such as veterinary infusion pumps [3] - The company reported a revenue growth of 15.45% year-on-year and a significant increase in net profit in Q1 2025, although cash flow management remains a concern [3] - The overseas revenue accounted for 81.56% of total revenue according to the 2024 annual report, indicating potential exposure to exchange rate fluctuations [3]

Core Viewpoint - The company has successfully obtained medical device registration for its BioCyte series flow cytometers in Malaysia, marking a significant step in expanding its market presence in Southeast Asia and serving global clinical and research users [1] Group 1: Product Development and Approval - The BioCyte series flow cytometers were developed by the company's subsidiary, Zhongsheng (Suzhou) Medical Technology Co., Ltd [1] - The registration number for the medical device is IVDA9463526–225393, indicating compliance with Malaysian regulatory standards [1] - The approval signifies that the product is now eligible for legal marketing, sales, and use in Malaysia [1] Group 2: Market Implications - The flow cytometry technology is widely used in clinical diagnostics and research, providing technical support for disease diagnosis, immunology research, and drug development [1] - The BioCyte series has already been applied in the domestic market due to its stable performance and accuracy in detection [1] - The company will collaborate with local authorized representative TRUSTDIAGNOSTICS SDN BHD to advance its market strategy in Malaysia [1]

Core Viewpoint - The company has successfully obtained medical device registration for its BioCyte series flow cytometers in Malaysia, marking a significant step in expanding its presence in the Southeast Asian market [1] Group 1: Product Development and Approval - The BioCyte series flow cytometers developed by the company's subsidiary, China Bio (Suzhou) Medical Technology Co., Ltd., have passed the Malaysian Medical Device Authority's review [1] - The registration number for the medical device is IVDA9463526–225393, indicating that the product is now legally qualified for sale and use in Malaysia [1] Group 2: Market Expansion and Strategy - The approval allows the company to expand its market reach in Southeast Asia and enhance its brand influence and market coverage internationally [1] - The product will be marketed through the local authorized representative, TRUST DIAGNOSTICS SDN BHD, facilitating the company's market entry strategy [1] Group 3: Technology Application - Flow cytometry technology is widely used in clinical diagnostics and research, providing technical support for disease diagnosis, immunology research, and drug development [1] - The BioCyte series has already been applied in the domestic market due to its stable performance and accuracy in detection [1]

Core Viewpoint - The company has successfully obtained medical device registration for its BioCyte series flow cytometers in Malaysia, marking a significant step in expanding its presence in the Southeast Asian market [1] Group 1: Product Development and Approval - The BioCyte series flow cytometers were developed by the company's subsidiary, Zhongsheng (Suzhou) Medical Technology Co., Ltd [1] - The registration number for the medical device is IVDA9463526–225393, indicating compliance with Malaysian regulatory standards [1] - The approval signifies that the product is now eligible for legal sales and use in Malaysia, enhancing the company's market opportunities [1] Group 2: Market Expansion and Strategy - The successful registration is expected to facilitate the company's expansion into the Southeast Asian market, aligning with its international development strategy [1] - The product will be marketed through a local authorized representative, TRUST DIAGNOSTICS SDN BHD, to enhance market penetration [1] - The flow cytometry technology is widely used in clinical diagnostics and research, providing support for disease diagnosis, immunology research, and drug development [1] Group 3: Regulatory Compliance - Malaysia has stringent regulatory standards for medical device approval, which the company successfully navigated by completing product testing and technical documentation submission [1] - The approval process underscores the company's commitment to meeting local regulatory requirements [1]

Core Viewpoint - The article emphasizes the importance of "long-term" and "contrarian" investment strategies, focusing on the essence of business and long-term trends rather than short-term market emotions and price trends [1][2]. Group 1: Investment Strategy - The company prioritizes finding investment opportunities with asymmetric risk-reward characteristics, specifically those that are significantly undervalued, rather than merely low-priced or low PB/PE stocks [2][3]. - Successful contrarian investment opportunities should not only be undervalued but also have a strong potential for future recognition and appreciation [2][3]. Group 2: Market Dynamics - Significant price discrepancies often arise from the market's tendency to linear extrapolate past performance, while the actual business environment may experience nonlinear changes [3][5]. - Historical examples illustrate how market expectations can lag behind actual industry performance, leading to substantial investment opportunities when the market eventually corrects its views [4][5]. Group 3: Value Drivers - Two key conditions for identifying attractive investment opportunities are: 1) a significant expectation gap where the market currently does not recognize the potential, and 2) strong value tension that will compel future recognition [3][7]. - The article highlights that strong value tension arises from powerful industry trends, excellent business fundamentals, and efficient operations, which together create a compelling investment case [9][12]. Group 4: Current Market Outlook - The biopharmaceutical market is expected to experience a recovery, with growth rates projected to improve from nearly zero to 1.2-1.4 times GDP growth, driven by easing pressures from social deflation and the adaptation to DRG policies [14][15]. - Despite the need to lower return expectations due to previous valuation recoveries, the overall outlook remains optimistic, particularly for domestic innovative drugs, U.S. biotech stocks, and innovative medical devices [15][17]. Group 5: Future Growth Potential - The domestic innovative drug sector is anticipated to maintain strong growth over the next decade, with revenue expected to increase from over 100 billion to 1 trillion, indicating significant market potential [17]. - The U.S. biotech sector is entering a commercialization phase that could unlock new multi-billion dollar market opportunities, while domestic innovative high-value consumables also show promise for substantial growth [17].

自願公告 中生（蘇州）醫療科技有限公司產品 獲發馬來西亞醫療器械註冊證 本公告乃由中生北控生物科技股份有限公司（「本公司」，與其附屬公司統稱為「本 集團」）自願作出，旨在提供本公司股東及潛在投資者有關本集團之最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司之附屬公司中生（蘇州）醫 療科技有限公司（「中生醫療」）自主研發之BioCyte 系列流式細胞儀，近日成功通 過馬來西亞醫療器械管理局的審核，正式獲得馬來西亞醫療器械註冊證，註冊編 號為IVDA9463526–225393。該註冊證的取得，標誌著相關產品已具備在馬來西亞 合法上市、銷售及使用的資格，也為本公司拓展東南亞市場、服務全球臨床與科研 使用者邁出了堅實有力的一步。 一、 產品基本情況 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任 何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 馬來西亞對醫療器械准入設有嚴格監管標準。中生醫療依據當地相關法規要 求，完成產品檢測、技術資料提交及審核程式，最終獲得馬來西亞醫療器械管 理 ...

Core Viewpoint - Haisheng Medical (920166.BJ) experienced a significant drop in stock price, closing at 29.56 yuan, a decrease of 14.29% after its listing on the Beijing Stock Exchange on February 12 [1] Group 1: Company Overview - Haisheng Medical issued up to 11,294,118 shares to unspecified qualified investors at a price of 12.64 yuan per share, ensuring that public shareholders hold at least 25% post-issue [1] - The total amount raised from the issuance was 142,757,651.52 yuan, with a net amount of 113,438,208.84 yuan after expenses, which is 25,698.72 million yuan less than originally planned [1] - The company plans to use the raised funds for upgrading and expanding its anesthetic monitoring and emergency medical device production, R&D testing center projects, and marketing service base construction [1] Group 2: Financial Details - The total issuance costs amounted to 2,931.94 million yuan, including 500.00 million yuan for sponsorship fees and 900.00 million yuan for underwriting fees [1] - On February 12, the stock closed at 34.49 yuan, reflecting a substantial increase of 172.86% from its initial listing price [2]

Core Viewpoint - The Beijing Stock Exchange (BSE) is accelerating the review and issuance of new stocks and refinancing, aiming to support the financing of small and medium-sized enterprises (SMEs) and enhance resource allocation towards technological innovation [1][6]. Group 1: New Stock Issuance - Two new stocks, Aide Technology and Haiseng Medical, were listed on the BSE, with Aide Technology's first-day closing price increasing by 176.79% and Haiseng Medical by 172.86% [2]. - Two new stocks, Tongbao Optoelectronics and Tongling Technology, are available for subscription, with expected fundraising of 304 million yuan and 462 million yuan respectively [2][3]. - The subscription funds for Haiseng Medical reached 685.8 billion yuan, while Tongbao Optoelectronics saw an increase to approximately 888.3 billion yuan [3]. Group 2: IPO and Financing - Three companies, Longxin Intelligent, Jiachen Intelligent, and Zhenhong Heavy Industry, are scheduled for IPO meetings, aiming to raise a total of 1.169 billion yuan [3][4]. - The BSE has maintained a high efficiency in IPO reviews, with three companies being reviewed in one week [3]. Group 3: Refinancing Initiatives - Jiangsu Lintai New Materials has announced a refinancing plan to raise 380 million yuan for projects in the new energy vehicle sector and high-end equipment manufacturing [5]. - The BSE's new refinancing measures allow companies to proceed with refinancing even if previous fundraising is not fully utilized, facilitating timely decision-making for SMEs [5][6]. - Since the BSE's inception, 14 companies have applied for refinancing, with 6 successfully registered, indicating a growing trend in refinancing demand among listed companies [7]. Group 4: Market Impact - The introduction of refinancing measures and the announcement of Lintai New Materials' plan are expected to invigorate the BSE market and encourage more successful cases [6]. - The BSE's support for innovative SMEs through refinancing is seen as crucial for their growth and development [6][7].

Core Viewpoint - Recent events involving Sino Medical, including related party transactions, new product approvals, share buybacks, and performance forecasts, have attracted market attention [1] Group 1: Related Party Transactions - The company held an extraordinary board meeting to review the proposal regarding the waiver of the preferential right to acquire shares in its subsidiary, which may involve changes in subsidiary equity [2] Group 2: Project Advancement - The company received a registration certificate from the National Medical Products Administration for a drug-eluting stent system, which is intended for the treatment of vascular stenosis in heart disease patients, potentially enriching the company's product portfolio [3] Group 3: Financial Movements - Since 2024, the company has been continuously repurchasing shares and announced a buyback plan of up to 300 million yuan in December 2025, with the founder also making multiple share purchases [4] Group 4: Performance Outlook - The company disclosed a performance forecast for 2025, expecting a year-on-year increase in net profit attributable to shareholders of 2767% to 3233%, primarily due to increased product sales and reduced expenses [5] Group 5: Stock and Fund Performance - The company's stock price increased by 2.12%, with a net inflow of 2.1817 million yuan in main funds, indicating high trading activity [6]